Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: A longitudinal, observational study from Turkey

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 5, 2010, Pages 407-413

  Erdogan, Ayten ^a   Karaman, Mehmet Goksin ^a   Ozdemir, Esra ^a   Yurteri, Nihal ^a   Tufan, Ali Evren ^b   Kurcer, Mehmet Ali ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b Department of Infectious Diseases and Clinical Microbiology   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; RISPERIDONE;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BILIRUBIN BLOOD LEVEL; CHILD; CONDUCT DISORDER; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; LIVER FUNCTION TEST; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; OBSERVATIONAL STUDY; OPPOSITIONAL DEFIANT DISORDER; PSYCHOSIS; SCHOOL CHILD; SIDE EFFECT; TIC; TREATMENT DURATION; TURKEY (REPUBLIC); WEIGHT CHANGE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LIVER; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; TURKEY;

EID: 77958603032     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0113     Document Type: Article

References (46)

1. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL: Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 15:869-884, 2005.
2. Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y: A review of liver function tests during treatment with atypical antipsychotic drugs: A chart review study. Prog Neuropsycho-pharmacol Biol Psychiatry 15:31:1255-1260, 2007.
3. Cepelak I, Lipovac K, Juretic D, Birek Z: Effects of neuroleptic phenothiazines on the activities of aminotransferases and gamma- glutamyltransferase in serum and liver. J Clin Chem Clin Biochem 24:583-587, 1986.
4. Chitturi S, George J: Hepatotoxicity of commonly used drugs: Non-steroidal antiinflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid lowering agents, psychotropic drugs. Semin Liver Dis 22:169-183, 2002.
5. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009.
6. Dincsoy HP, Saelinger DA: Haloperidol-induced chronic cholestatic liver disease. Gastroenterology 83:694-700, 1982.
7. Dumotier G, Cabaret W, Stamatiais L, Saba G, Benadriha R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D: Hepatic tolerance of atypical antipsychotic drugs. Encephale 28:542-551, 2002.
8. Erdogan A, Atasoy N, Akkurt H, Ozturk D, Karaahmet E, Yalug I, Yalug K, Ankarali H, Balcioglu I: Risperidone and liver function tests in children and adolescents: A short-term prospective study. Prog Neuropsychopharmacol Biol Psychiatry 32:849-857, 2008.
9. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516, 2000.
10. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B: Risperidone disruptive behavior study group. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677-684, 2004.
11. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A: Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm 114:273-280, 2007.
12. Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, Rater MA, Tarazi RA, Kim GS, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser RC, Nowlin ZM: A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11:239-250, 2001.
13. Gaertner I, Altendorf K, Batra A, Gaertner HJ: Relevance of liver enzyme elevations with four different neuroleptics: A retrospective review of 7,263 treatment courses. J Clin Psychopharmacol 21:215-222, 2001.
14. Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S: Risperidone versus clonidine in the treatment of children and adolescents with Tourette's Syndrome. J Am Acad Child Adolesc Psychiatry 41:330-336, 2002.
15. Garcia-Unzueta MT, Herran A, Sierra-Biddle D, Amado JA, Vazquez-Barquero JL, Alvarez C: Alterations of liver function test in patients treated with antipsychotics. J Clin Lab Anal 17:216-218, 2003.
16. Gonzalez-Heydrich J, Raches D, Wilens TE, Leichtner A, Mezza-cappa E: Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry 42:1227-1233, 2003.
17. Holtmann M, Kopf D, Mayer M, Bechtinger E, Schmidt MH: Ris-peridone associated steatohepatitis and excessive weight-gain. Pharmacopsychiatry 36:206-207, 2003.
18. Hummer M, Kurz M, Kurtzhaler I, Oberbauer H, Miller C, Fleischhacker WW: Hepatotoxicity of clozapine. J Clin Pharmacol 17: 314-317, 1997.
19. Kafali G, Erselcan T, Tanzer F: Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pe-diatr (Phila) 38:93-98, 1999.
20. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM: Weight gain in adolescents treated with risperidone and conventional antipsy-chotics over six months. J Child Adolesc Psychopharmacol 8:151-159, 1998.
21. Krebs S, Dormann H, Muth-Selbach U, Hahn EG, Brune K, Schneider HT: Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol 13:67-69, 2001.
22. Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D: Case study: Risperidone induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 36:701-705, 1997.
23. Landau J, Martin A: J Is liver function monitoring warranted during risperidone treatment? Am Acad Child Adolesc Psychiatry 37:1007-1008, 1998.
24. Llinares Tello F, Hernandez Prats C, Bosacoma Ros N, Perez Martinez E, Climent Grana E, Navarro Polo JN, Ordovás Baines JP: Acute cholestatic hepatitis probably associated with risperidone. Int J Psychiatry Med 35:199-205, 2005.
25. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA: Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140-147, 2002.
26. Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, Leckman JF: Risperidone-associated weight gain in children and adolescents: A retrospective chart review. J Child Adolesc Psy-chopharmacol 10:259-268, 2000.
27. Masi G, Cosenza A, Mucci M, Brovedani P: A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 64:1039-1047, 2003.
28. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D; Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002.
29. Moran JR, Ghishan FK, Halter SA, Greene HL: Steatohepatitis in obese children: A cause of chronic liver dysfunction. Am J Gas-troenterol 78:374-377, 1983.
30. Mouradian-Stamatiadis L, Dumortier G, Januel D, Delmas BA, Cabaret W: Liver function tests during treatment with antipsychotic drugs: A case series of 23 patients. Prog Neuro-Psychopharmacol Biol Psychiatry 26:1409-1411, 2002.
31. Obata T: Intrahepatic cholestasis and hyperbilirubinemia in ethynyl estradiol and chlorpromazine-treated rats. Gastroenterol Jpn 18:538-548, 1983.
32. Pae CU, Lim HK, Kim TS, Kim JJ, Lee CU, Lee SJ, Lee C, Paik IH: Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psy-chopharmacol 20:173-176, 2005.
33. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R: Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337-343, 2002.
34. Safer DJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24:429-436, 2004.
35. Schatzberg AF: Safety and tolerability of antidepressants: Weighing the impact on treatment decisions. J Clin Psychiatry 68(Suppl 8):26-34, 2007.
36. Serretti A, De Ronchi D, Lorenzi C, Berardi D: New antipsychotics and schizophrenia: A review on efficacy and side effects. Curr Med Chem 11:343-358, 2004.
37. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:634-641, 2004.
38. Sherlock S, Dooley J: Diseases of the Liver and Biliary System, 9th ed. Oxford, England, and Boston: Blackwell Scientific Publications, 1993.
39. Sikich L,Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsycho-pharmacology 29:133-145, 2004.
40. Steiner H: Practice parameters for the assessment and treatment of children and adolescents with conduct disorders. J Am Acad Child Adolesc Psychiatry 36(suppl 10):122-139, 1997.
41. Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL: Risperidone induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 9:93-98, 1999.
42. Thomas L. In: Enzymdiagnostik. Thomas L, ed. Labor und Diagnose. Marburg: Medizinische Verlags-Gesellschaft, 1995, pp 39-160.
43. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.
44. Whitworth AB, Liensberger D, Fleischhacker WW: Transient increase of liver enzymes induced by risperidone: Two case reports. J Clin Psychopharmacol 19:475-476, 1999.
45. Wigal S, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, Swanson J, Wigal S, Abikoff H, Kollins S, McCracken J, Riddle M, Posner K, Ghuman J, Davies M, Thorp B, Stehli A: Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 45:1294-1303, 2006. (Pubitemid 44665446)
46. Zuddas A, Di Martino A, Muglia P, Cianchetti C: Long-term risper-idone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10:79-90, 2000.